期刊文献+

利培酮治疗12例精神分裂症的临床分析 被引量:1

Risperidone Therapy Clinical Analysis of 12 Patients with Schizophrenia
下载PDF
导出
摘要 目的探究利培酮在治疗精神分裂症中的临床效果。方法选取2013年7月到2014年5月来我院就就诊的12例精神分裂症患者随机分为观察组与对照组各6例,对观察组患者行利培酮治疗,对照组患者行齐拉西酮治疗,比较两组患者药物使用后治愈效果。结果采用利培酮治疗的小组各方面情况均优于采用齐拉西酮治疗的小组(P<0.05),差异具有统计学意义。结论利培酮用于精神分裂症患者的治疗中效果好,不良反应少,对患者疾病恢复有很大的帮助,值得临床推广使用。 ObjectiveTo explore the clinical effect of risperdal in the treatment of schizophrenia.Methods In July 2013 to May 2014 to our hospital clinic of 12 patients with schizophrenia were randomly divided into observation group and the control group (n=6), the observation group patients risperidone treatment, control group patients ziprasidone treatment, compared two groups of patients after drug use cure effect. Results Treated with risperidone group various aspects condition is superior to the ziprasidone treatment group(P〈0.05), difference has statistical significance.Conclusion Risperidone in the treatment of patients with schizophrenia, good effect, less adverse reaction, is of great help to patients with disease recovery, worth clinical promotion use.
作者 孙振芹
机构地区 朝阳市康宁医院
出处 《中国卫生标准管理》 2014年第19期116-118,共3页 China Health Standard Management
关键词 利培酮 精神分裂症 临床分析 Risperidone Schizophrenia Clinical analysis
  • 相关文献

二级参考文献22

  • 1吴仁容,李乐华.新型抗精神病药:阿立哌唑[J].国外医学(精神病学分册),2004,31(3):177-179. 被引量:380
  • 2王从杰,孙静,张志珺.抗精神病药与2型糖尿病[J].临床精神医学杂志,2004,14(5):313-314. 被引量:18
  • 3高哲石.精神分裂症的药物治疗进展[J].世界临床药物,2007,28(4):204-208. 被引量:32
  • 4Elis O, Caponigro JM, Kring AM. Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions[J]. C lin Psychol Rev, 2013,33 ( 8 ) : 914 - 928.
  • 5Malchow B, Reich - Erkelenz D, Oertel - Knochel V, et al. The effects of physical exercise in schizophrenia and affective disorders[J]. Eur Arch Psychiatry Clin Neurosci, 2013,263 (6) : 451 - 467.
  • 6Moteshafi H, Stip E. Comparing tolerability profile of quetiapine, risperi- done, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta - analysis [J ]. Expert Opin Drug Saf, 2012,11 (5): 713 - 732.
  • 7Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? [ J]. Arch Gen Psychiatry, 2007,64(10) : 1123-1131.
  • 8Cohon CW, Manderscheid RW. Congruencies in increased mortal- ity rates, yeats of potential life lost, and causes of death among public mentalhealth clients in eight states [ J] Prey Chronic Dis, 2006,3 ( 2 ) : A42.
  • 9Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenis[ J ]. Hum psychopharmacol, 2004, 19 (8) : 559- 563.
  • 10Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic [ J ] Am J Psychiatry, 2006,163 (4) :611- 622.

共引文献39

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部